Renji Hospital

Running trials

• Enrolling by invitation

  Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection

  NCT07833046· Source

• Not yet recruiting

  GBP-213 in Patients With Autosomal Dominant Polycystic Kidney Disease

  NCT07891364· Early phase 1· Source

• Recruiting

  Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure

  NCT07575672· Phase 3· Source

• Recruiting

  Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi®

  NCT07663526· Phase 4· Source

• Not yet recruiting

  A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

  NCT07632235· Phase 1/2· Source

• Not yet recruiting

  Dual GIP/GLP-1 Receptor Agonist in Obese Women Before Frozen Embryo Transfer

  NCT07811895· Source

• Recruiting

  Plasma DNA Methylation for Preoperative Classification of Renal Masses

  NCT07874542· Source

• Not yet recruiting

  AI-Assisted Novel rbcDNA Detection for Early Gastric Cancer Diagnosis

  NCT07782294· Source

• Recruiting

  A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis

  NCT07521007· Phase 2· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Source

• Recruiting

  To Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced/Metastatic Renal Cancer

  NCT07647744· Phase 1· Source

• Not yet recruiting

  The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching

  NCT07678645· Phase 2· Source

• Recruiting

  A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia

  NCT06712654· Phase 2· Source

• Not yet recruiting

  HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUC

  NCT07591805· Phase 2· Source

• Recruiting

  A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

  NCT07409181· Phase 2· Source

• Recruiting

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· Phase 3· Source

• Recruiting

  Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

  NCT07283692· Phase 2· Source

• Recruiting

  A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

  NCT07276958· Phase 1· Source

• Recruiting

  Biochemical Response and Clinical Outcomes in Patients With PBC

  NCT07449793· Source

• Recruiting

  Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients

  NCT07266116· Phase 1/2· Source

• Recruiting

  A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus

  NCT07323173· Phase 1· Source

• Recruiting

  Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer

  NCT07366528· Phase 3· Source

• Recruiting

  Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)

  NCT07265570· Phase 2· Source

• Recruiting

  A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA

  NCT07282353· Phase 3· Source

• Recruiting

  Feasibility Study of Diaphragm Synchronized Pacing (DSP) Via the Left Inferior Phrenic Vein (LIPV) Approach

  NCT07392749· Source

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Source

• Recruiting

  Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer

  NCT07187635· Source

• Recruiting

  Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

  NCT07180160· Phase 2· Source

• Not yet recruiting

  A Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin Combined With PD-1 Inhibitor and Radiotherapy as Bladder-preserving Therapy in Patients With Localized HER2-high Expressing Muscle-invasive Bladder Urothelial Carcinoma Following Maximal Transurethral Resection

  NCT07142200· Phase 2· Source

• Recruiting

  Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer

  NCT07180082· Phase 2· Source

• Recruiting

  Trastuzumab Deruxtecan in Advanced Breast Cancer

  NCT07180264· Source

• Recruiting

  A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

  NCT07066657· Phase 1· Source

• Recruiting

  A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy

  NCT06963827· Phase 3· Source

• Not yet recruiting

  A Real-world Study of Liposomal Irinotecan (Onivyde)-Based Therapy in Patients With Locally Advanced/Metastatic Pancreatic Cancer in China

  NCT07026123· Source

• Active, not recruiting

  A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

  NCT06880744· Phase 3· Source

• Recruiting

  ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression

  NCT07327034· Phase 2· Source

• Recruiting

  A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

  NCT06933472· Phase 3· Source

• Recruiting

  A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

  NCT06764615· Phase 2· Source

• Not yet recruiting

  Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC

  NCT06916117· Phase 2· Source

• Recruiting

  A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary Syndrome.

  NCT06788431· Early phase 1· Source

• Not yet recruiting

  Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)

  NCT06859931· Phase 2· Source

• Not yet recruiting

  Early Identification and Treatment of Rare Cardiomyopathy Cohorts

  NCT06794710· Source

• Recruiting

  A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

  NCT07673029· Phase 3· Source

• Recruiting

  Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer

  NCT07026110· Source

• Recruiting

  Trop2-targeted immunoPET Imaging of Solid Tumors

  NCT06851663· Phase 2/3· Source

• Recruiting

  CD70-targeted immunoPET Imaging of Malignant Cancers

  NCT06852638· Phase 2· Source

• Not yet recruiting

  Study of Acupuncture to Control Weight and Improve Pregnancy Rates in Overweight/Obese PCOS Patients

  NCT06717087· Source

• Recruiting

  Target-specific immunoPET Imaging of Digestive System Carcinoma

  NCT06715839· Source

• Recruiting

  COLORECTUM+ Digital System for Postoperative Quality Improvement in Colorectal Cancer

  NCT06685497· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Metastatic breast cancer10 recruiting
• Pancreatic cancer10 recruiting
• Bladder cancer9 recruiting
• Gastric and esophageal cancer9 recruiting
• Lupus (SLE)7 recruiting
• Prostate cancer7 recruiting
• Colorectal cancer6 recruiting
• Liver and biliary tract cancer5 recruiting
• Cervical cancer4 recruiting
• Coronary artery disease4 recruiting
• Kidney cancer4 recruiting
• Lung cancer4 recruiting
• Primary biliary cholangitis4 recruiting
• Childhood cancers3 recruiting
• Chronic kidney disease3 recruiting
• Crohn's disease3 recruiting
• Systemic sclerosis (scleroderma)3 recruiting
• Alzheimer disease2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Head and neck cancer2 recruiting
• Heart failure2 recruiting
• Multiple myeloma2 recruiting
• Obesity2 recruiting
• Ovarian cancer2 recruiting
• Triple-negative breast cancer2 recruiting
• Ulcerative colitis2 recruiting
• Amyloidosis1 recruiting
• Asthma1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Endometrial cancer1 recruiting
• Epilepsy1 recruiting
• Follicular lymphoma1 recruiting
• High blood pressure1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• IgA nephropathy1 recruiting
• Mantle cell lymphoma1 recruiting
• Multiple sclerosis1 recruiting
• Myasthenia gravis1 recruiting
• Neuroendocrine tumours1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Polycystic kidney disease1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Rheumatoid arthritis1 recruiting
• Thyroid cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Source

• Completed

  Construction of Clinical Diagnostic Model for Pulmonary Hypertension

  NCT06979011· Source

• Completed

  A General Anesthesia Regimen for DBS Surgery in Patients With PD

  NCT06658132· Source

• Completed

  Validation of the Reliability and Validity of the New Endoscopic Scoring System for Ulcerative Colitis (CAT-DESIRE Score) and Verification of Its Clinical Practicability

  NCT07608198· Source

• Completed

  A Multimodal Predictive Recurrence Score for Patients With Clear Cell Renal Cell Carcinoma

  NCT06656039· Source

• Completed

  Development of AI Model for Renal Tumor Diagnosis Using CT and Lab Tests

  NCT06761742· Source

• Completed

  A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)

  NCT06081621· Phase 2· Source

• Completed

  Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)

  NCT05861128· Phase 3· Source

• Completed

  Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)

  NCT05861102· Phase 3· Source

• Completed

  A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis

  NCT05770609· Phase 2· Source

• Completed

  AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia

  NCT07030595· Phase 3· Source

• Completed

  A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China

  NCT05658484· Phase 4· Source

• Completed

  Evaluation of Lung Metastases Based on Ultrashort Echo Time MRI

  NCT05763173· Source

• Completed

  TESTING -ON Post-Trial ObservatioNal Cohort Study

  NCT05434325· Source

• Completed

  A Multicenter Cross-sectional Study on Mental Health of Patients With Multiple Myeloma

  NCT05620420· Source

• Completed

  Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)

  NCT05522231· Phase 2/3· Source

• Completed

  18F-PBR06/Total Body PET Imaging in Patients With STEMI

  NCT05269446· Source

• Completed

  Comparison Between Upgraded '2C3L' vs. PVI Approach for Catheter Ablation of Persistent Atrial Fibrillation

  NCT04497376· Source

• Completed

  Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma

  NCT04672330· Phase 2· Source

• Completed

  A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

  NCT04172675· Phase 2· Source

• Completed

  A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

  NCT04108208· Phase 4· Source

• Completed

  Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)

  NCT03748953· Phase 3· Source

• Completed

  A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

  NCT03217812· Phase 3· Source

• Completed

  Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)

  NCT03062358· Phase 3· Source

• Completed

  Transanal Versus Laparoscopic Total Mesorectal Excision For Rectal Cancer

  NCT02966483· Source

• Completed

  AccuIMR Predicts Microvascular Obstruction and Infarct Size in STEMI Patients

  NCT06947564· Source

Trial sites

• RenJi Hospital2 trials
• Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University,1 trial
• Department of nephrology , Renji Hospital, Shanghai Jiao Tong University School of Medicine1 trial
• Department of Radiology, Renji Hospital, School of Medicine, Shanghai Jiaotong University1 trial
• Department of Rheumatology, RenJi Hospital, School of Medicine, Shanghai JiaoTong University1 trial
• RenJi Hospital35 trials
• Renji Hospital, Medical College, Shanghai Jiaotong University1 trial
• Renji Hospital, School of Medicine, Shanghai Jiaotong University10 trials
• Renji Hospital, School of Medicine, Shanghai Jiao Tong University17 trials
• Renji Hospital,Shanghai1 trial
• Renji Hospital, Shanghai Jiao Tong University1 trial
• Renji Hospital, Shanghai Jiaotong University School of Medecine1 trial
• Renji Hospital, Shanghai Jiaotong University School of Medicine43 trials
• Renji Hospital, Shanghai Jiaotong University School of Medicine /ID# 1658261 trial
• Renji Hospital, Shanghai Jiaotong University School of Medicine /ID# 2107051 trial
• Renji Hospital, Shanghai Jiaotong University School of Medicine /ID# 2112301 trial
• Renji Hospital, Shanghai Jiaotong University School of Medicine /ID# 2244201 trial
• Renji Hospital, Shanghai Jiaotong University School of Medicine /ID# 2634351 trial
• Renji Hospital, Shanghai Jiaotong University School Of Medicine /ID# 2701651 trial
• Renji Hospital, Shanghai Jiaotong University School of Medicine /ID# 2756581 trial
• Renji Hospital, Shanghai Jiatong Uni. School of Medicine1 trial
• Renji Hosp,Shanghai Jiao Tong University School of Medicine (Site 0017)1 trial
• Renji Hosp,Shanghai Jiao Tong University School of Medicine (Site 3042)1 trial
• Renji Shanghai Hospital1 trial
• Shanghai Jiaotong University School of Medcine, Renji Hospital1 trial
• Shanghai Jiaotong University School of Medicine, Renji Hospital9 trials
• Shanghai Jiao Tong University School of Medicine, Renji Hospital6 trials
• Shanghai Jiao Tong University School of Medicine (SJTUSM)-Renji Hospital2 trials
• Shanghai Jiao Tong University School of Medicine (SJTUSM) - Renji Hospital - Eastern Branch1 trial
• Shanghai Renji Hospital4 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Liver and biliary tract cancer110 works · 9 trials
• Colorectal cancer82 works · 7 trials
• Prostate cancer62 works · 9 trials
• Gastric and esophageal cancer46 works · 11 trials
• Pancreatic cancer44 works · 10 trials
• Ovarian cancer30 works · 2 trials
• Lupus (SLE)29 works · 9 trials
• Kidney cancer29 works · 9 trials
• Bladder cancer29 works · 12 trials
• Systemic sclerosis (scleroderma)12 works · 4 trials
• Thyroid cancer11 works · 1 trials
• Myasthenia gravis7 works · 1 trials
• Primary biliary cholangitis6 works · 4 trials
• ANCA-associated vasculitis4 works · 0 trials
• IgA nephropathy4 works · 4 trials